RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk

Journal of Bone and Mineral Research

Volumn 29, Issue 2, 2014, Pages 450-457

  Samelson, Elizabeth J ^a   Miller, Paul D ^b   Christiansen, Claus ^c   Daizadeh, Nadia S ^d   Grazette, Luanda ^e   Anthony, Mary S ^d   Egbuna, Ogo ^d   Wang, Andrea ^d   Siddhanti, Suresh R ^d   Cheung, Angela M ^f   Franchimont, Nathalie ^g   Kiel, Douglas P ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b University of Colorado Health Sciences Center   (United States)

^c CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

^d AMGEN INC   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f UNIVERSITY HEALTH NETWORK   (Canada)

^g BIOGEN   (United States)

Author keywords

AORTIC CALCIFICATION; CARDIOVASCULAR; DENOSUMAB; OSTEOPOROSIS; RANKL OPG

Indexed keywords

CALCIUM; DENOSUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; PLACEBO; RALOXIFENE; VITAMIN D;

ADULT; AGED; AORTA CALCIFICATION; AORTA DISEASE; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DIET SUPPLEMENTATION; DISEASE COURSE; FEMALE; HEART INFARCTION; HUMAN; INCIDENCE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MEDICAL DICTIONARY FOR REGULATORY ACTIVITIES; MIDDLE AGED; OSTEOPOROSIS; PERCUTANEOUS CORONARY INTERVENTION; POSTMENOPAUSE; POTENTIAL DIFFERENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPINE FRACTURE; SPINE RADIOGRAPHY; VERY ELDERLY; VITAMIN SUPPLEMENTATION;

AORTIC CALCIFICATION; CARDIOVASCULAR; DENOSUMAB; OSTEOPOROSIS; RANKL/OPG;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; AORTIC DISEASES; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RANK LIGAND; VASCULAR CALCIFICATION;

EID: 84892767224     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2043     Document Type: Article

References (47)

1. Wilson PW, Kauppila LI, O'Donnell CJ, et al. Abdominal aortic calcific deposits are an important predictor of vascular morbidity and mortality. Circulation. 2001; 103 (11): 1529-34.
2. Kiel DP, Kauppila LI, Cupples LA, Hannan MT, O'Donnell CJ, Wilson PW,. Bone loss and the progression of abdominal aortic calcification over a 25 year period: the Framingham Heart Study. Calcif Tissue Int. 2001; 68 (5): 271-6.
3. Naves M, Rodriguez-Garcia M, Diaz-Lopez JB, Gomez-Alonso C, Cannata-Andia JB,. Progression of vascular calcifications is associated with greater bone loss and increased bone fractures. Osteoporos Int. 2008; 19 (8): 1161-6.
4. Hak AE, Pols HA, van Hemert AM, Hofman A, Witteman JC,. Progression of aortic calcification is associated with metacarpal bone loss during menopause: a population-based longitudinal study. Arterioscler Thromb Vasc Biol. 2000; 20 (8): 1926-31.
5. Bagger YZ, Tankõ LB, Alexandersen P, Qin G, Christiansen C;, Prospective Epidemiological Risk Factors Study Group. Radiographic measure of aorta calcification is a site-specific predictor of bone loss and fracture risk at the hip. J Intern Med. 2006; 259 (6): 598-605.
6. Rajzbaum G, Roger VL, Bézie Y, et al. French women, fractures and aortic calcifications. J Intern Med. 2005; 257 (1): 117-9.
7. Szulc P, Kiel DP, Delmas PD,. Calcifications in the abdominal aorta predict fractures in men: MINOS study. J Bone Miner Res. 2008; 23 (1): 95-102.
8. Schulz E, Arfai K, Liu X, Sayre J, Gilsanz V,. Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab. 2004; 89 (9): 4246-53.
9. Farhat GN, Cauley JA, Matthews KA, et al. Volumetric BMD and vascular calcification in middle-aged women: the Study of Women's Health Across the Nation. J Bone Miner Res. 2006; 21 (12): 1839-46.
10. Hyder JA, Allison MA, Wong N, et al. Association of coronary artery and aortic calcium with lumbar bone density: the MESA Abdominal Aortic Calcium Study. Am J Epidemiol. 2009; 169 (2): 186-94.
11. Iwamoto J, Matsumoto H, Takeda T, Sato Y, Uzawa M,. A radiographic study on the associations of age and prevalence of vertebral fractures with abdominal aortic calcification in Japanese postmenopausal women and men. J Osteoporos. 2010; 2010: 748380.
12. Hofbauer LC, Brueck CC, Shanahan CM, Schoppet M, Dobnig H,. Vascular calcification and osteoporosis - from clinical observation towards molecular understanding. Osteoporos Int. 2007; 18 (3): 251-9.
13. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998; 93 (2): 165-76.
14. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997; 89 (2): 309-19.
15. Kostenuik PJ,. Osteoprotegerin and RANKL regulate bone resorption, density, g eometry and strength. Curr Opin Pharmacol. 2005; 5 (6): 618-25.
16. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009; 361 (8): 756-65.
17. Kiechl S, Werner P, Knoflach M, Furtner M, Willeit J, Schett G,. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. Expert Rev Cardiovasc Ther. 2006; 4 (6): 801-11.
18. Schoppet M, Preissner KT, Hofbauer LC,. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol. 2002; 22 (4): 549-53.
19. Browner WS, Lui LY, Cummings SR,. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab. 2001; 86 (2): 631-7.
20. Bucay N, Sarosi I, Dunstan CR, et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998; 12 (9): 1260-8.
21. Min H, Morony S, Sarosi I, et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med. 2000; 192 (4): 463-74.
22. Morony S, Tintut Y, Zhang Z, et al. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. Circulation. 2008; 117 (3): 411-20.
23. Bennett BJ, Scatena M, Kirk EA, et al. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice. Arterioscler Thromb Vasc Biol. 2006; 26 (9): 2117-24.
24. Price PA, June HH, Buckley JR, Williamson MK,. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol. 2001; 21 (10): 1610-6.
25. Jono S, Ikari Y, Shioi A, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation. 2002; 106 (10): 1192-4.
26. Knudsen ST, Foss CH, Poulsen PL, Andersen NH, Mogensen CE, Rasmussen LM,. Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol. 2003; 149 (1): 39-42.
27. Kiechl S, Schett G, Wenning G, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation. 2004; 109 (18): 2175-80.
28. Ozkok A, Caliskan Y, Sakaci T, et al. Osteoprotegerin/RANKL axis and progression of coronary artery calcification in hemodialysis patients. Clin J Am Soc Nephrol. 2012; 7 (6): 965-73.
29. Schoppet M, Schaefer JR, Hofbauer LC,. Low serum levels of soluble RANK ligand are associated with the presence of coronary artery disease in men. Circulation. 2003; 107 (11): e76; author reply e76.
30. Kiechl S, Schett G, Schwaiger J, et al. Soluble receptor activator of nuclear factor-kappa B ligand and risk for cardiovascular disease. Circulation. 2007; 116 (4): 385-91.
31. Mosca L, Barrett-Connor E, Wenger NK, et al. Design and methods of the Raloxifene Use for The Heart (RUTH) study. Am J Cardiol. 2001; 88 (4): 392-5.
32. Keech CA, Sashegyi A, Barrett-Connor E,. Year-by-year analysis of cardiovascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial. Curr Med Res Opin. 2005; 21 (1): 135-40.
33. Kauppila LI, Polak JF, Cupples LA, Hannan MT, Kiel DP, Wilson PW,. New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. Atherosclerosis. 1997; 132 (2): 245-50.
34. Jamal SA, Ljunggren O, Stehman-Breen C, et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res. 2011; 26 (8): 1829-35.
35. Diamandopoulos A, Goudas P, Arvanitis A,. Comparison of estimated creatinine clearance among five formulae (Cockroft-Gault, Jelliffe, Sanaka, simplified 4-variable MDRD and DAF) and the 24hours-urine-collection creatinine clearance. Hippokratia. 2010; 14 (2): 98-104.
36. Froissart M, Rossert J, Jacquot C, Paillard M, Houillier P,. Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol. 2005; 16 (3): 763-73.
37. Matsushita K, Mahmoodi BK, Woodward M, et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA. 2012; 307 (18): 1941-51.
38. Earley A, Miskulin D, Lamb EJ, Levey AS, Uhlig K,. Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review. Ann Intern Med. 2012; 156 (11): 785-95.
39. Stevens LA, Zhang Y, Schmid CH,. Evaluating the performance of equations for estimating glomerular filtration rate. J Nephrol. 2008; 21 (6): 797-807.
40. Nakamura S, Ishibashi-Ueda H, Niizuma S, Yoshihara F, Horio T, Kawano Y,. Coronary calcification in patients with chronic kidney disease and coronary artery disease. Clin J Am Soc Nephrol. 2009; 4 (12): 1892-00.
41. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY,. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351 (13): 1296-305.
42. Schiffrin EL, Lipman ML, Mann JF,. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007; 116 (1): 85-97.
43. Tankõ LB, Qin G, Alexandersen P, Bagger YZ, Christiansen C,. Effective doses of ibandronate do not influence the 3-year progression of aortic calcification in elderly osteoporotic women. Osteoporosis Int. 2005; 16 (2): 184-90.
44. Cannata-Andia JB, Rodriguez-Garcia M, Carrillo-Lopez N, Naves-Diaz M, Diaz-Lopez B,. Vascular calcifications: pathogenesis, management, and impact on clinical outcomes. J Am Soc Nephrol. 2006; 17 (12 Suppl 3): S267-73.
45. Ominsky MS, Li X, Asuncion FJ, et al. RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats. J Bone Miner Res. 2008; 23 (5): 672-82.
46. Helas S, Goettsch C, Schoppet M, et al. Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice. Am J Pathol. 2009; 175 (2): 473-8.
47. Crisafulli A, Micari A, Altavilla D, et al. Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. Clin Sci (Lond). 2005; 109 (4): 389-95.